Gene · 6012
RIEG2: Rieger syndrome 2
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. RIEG2: Rieger syndrome 2. Genes, record 6012. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6012
On this page
Gene
- Symbol
- RIEG2
- Name
- Rieger syndrome 2
- NCBI Gene ID
- 6012
- Aliases
- ARS, RGS2
- Type
- unknown
Source NCBI Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,170
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RIEG2 papers | Newest fiscal year |
|---|---|---|---|
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 30 | 2025 |
| ZIADK031126 | Computer Modeling of G Protein-Coupled Receptors | 16 | 2025 |
| ZIADK031115 | Functionalized Congeners of Bioactive Compounds | 11 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 10 | 2025 |
| P01CA163227 | Androgen Receptor Action in Castration Resistant Prostate Cancer | 9 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 8 | 2025 |
| ZIADK031116 | Development of P2Y Receptor Ligands | 7 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 6 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,170Source NIH's project files
See all 1,170 nih grantsPapers2,400
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Age-dependent myositis-specific autoantibody profiles and CD8+ T-cell signatures in juvenile dermatomyositis. | Immunol Med | 2026 | 42808692 | PubTator, text mining | PubMed |
| Neutrophil-poor inflammatory synovial fluid in antisynthetase syndrome with confirmed anti-aminoacyl-tRNA synthetase antibodies. | Rheumatology (Oxford) | 2026 | 42773516 | PubTator, text mining | PubMed |
| Biochemical Clues in unravelling the Puzzle of Anti- synthetase Syndrome. | EJIFCC | 2026 | 42730038 | PubTator, text mining | PubMed |
| Complete remission and relapse in the treatment of idiopathic inflammatory myopathies: a retrospective cohort study. | Mod Rheumatol | 2026 | 42623261 | PubTator, text mining | PubMed |
| Prostatic Androgen Receptor Expression in Men with Prostate Cancer. | Niger Postgrad Med J | 2026 | 42616976 | PubTator, text mining | PubMed |
| Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics. | Clin Pharmacol Ther | 2026 | 42565496 | PubTator, text mining | PubMed |
| The miR-335-5p/DKK1/autophagy axis regulates TNF-α-mediated dysfunction of dental pulp stem cells. | In Vitro Cell Dev Biol Anim | 2026 | 42496832 | PubTator, text mining | PubMed |
| From empirical screening to lipid trolling: the evolution of extrahelical allosteric modulators of A1 and A3 adenosine receptors. | Med Chem Res | 2026 | 42446533 | PubTator, text mining | PubMed |
| Anti-PM/Scl antibody-positive myositis with muscle pathology resembling anti-synthetase syndrome. | Mod Rheumatol Case Rep | 2026 | 42436615 | PubTator, text mining | PubMed |
| Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365. | J Med Chem | 2026 | 42430428 | PubTator, text mining | PubMed |
1 to 10 of 2,400
See all 2,400 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6012
GET https://conductscience.org/api/genes/v1/6012/grants?page=2